The prevalence of NQO1 overexpression in such a wide variety of malignant cancers (>90% in pancreatic cancers with KRAS mutation, >80% nonsmall cell lung cancer (NSCLC), >60% breast cancer, >60% prostate cancer, >45% head and neck, and >60% colon cancers [109]) suggests that this combination therapy may have significant future potential, especially in cancers in which prognosis is currently poor, such as head and neck cancer, pancreatic cancer and NSCLC [117,120,121,122,123,124,125,126]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.